KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Guardant Health (GH) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to 37.33%.

  • Guardant Health's EBITDA Margin rose 239500.0% to 37.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.02%, marking a year-over-year increase of 254000.0%. This contributed to the annual value of 60.02% for FY2024, which is 401100.0% up from last year.
  • As of Q3 2025, Guardant Health's EBITDA Margin stood at 37.33%, which was up 239500.0% from 45.85% recorded in Q2 2025.
  • Guardant Health's EBITDA Margin's 5-year high stood at 37.33% during Q3 2025, with a 5-year trough of 137.12% in Q1 2021.
  • Its 5-year average for EBITDA Margin is 89.93%, with a median of 90.84% in 2021.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -854000bps in 2021, then soared by 649700bps in 2024.
  • Guardant Health's EBITDA Margin (Quarter) stood at 90.84% in 2021, then decreased by -27bps to 115.15% in 2022, then decreased by -11bps to 127.38% in 2023, then skyrocketed by 51bps to 62.42% in 2024, then skyrocketed by 40bps to 37.33% in 2025.
  • Its EBITDA Margin stands at 37.33% for Q3 2025, versus 45.85% for Q2 2025 and 54.57% for Q1 2025.